Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in Maryland: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (189 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 18 | 882 | 14% |
| 2020 | 13 | 691 | 15% |
| 2021 | 14 | 681 | 19% |
| 2022 | 14 | 709 | 22% |
| 2023 | 13 | 735 | 25% |
| 2024 | 15 | 785 | 28% |
| 2025 from claims | – | 828 677–977 | 29% |
| 2026 forecast | – | 856 679–1,084 | 29% |
| 2027 forecast | – | 870 655–1,161 | 29% |
| 2028 forecast | – | 883 636–1,233 | 30% |
| 2029 forecast | – | 897 622–1,302 | 31% |
| 2030 forecast | – | 911 610–1,370 | 31% |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 82% of the cases CMS names in Maryland; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 21% inpatient hospital, 79% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~860 | ~170 | ~690 |
| 2027 · ~870 | ~170 | ~700 |
| 2028 · ~880 | ~170 | ~720 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 19% (21% in 2025), hospital outpatient about 81% (79% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 41 | 2,404−0.5%/yr | −0.5%/yr | 1.2 | 0% | 3,280 in 2030+5.3%/yr |
| Florida | 36 | 2,306+0.2%/yr | +0.2%/yr | 1.1 | 0% | 2,680 in 2030+2.5%/yr |
| North Carolina | 14 | 1,012−3%/yr | −3%/yr | 1.1 | 0% | 1,160 in 2030+2.3%/yr |
| Tennessee | 17 | 950−5%/yr | −5%/yr | 1.5 | 0% | 1,060 in 2030+1.8%/yr |
| Georgia | 20 | 915−0.7%/yr | −0.7%/yr | 1.2 | 0% | 960 in 2030+0.8%/yr |
| Virginia | 21 | 880−2%/yr | −2%/yr | 0.9 | 0% | 1,030 in 2030+2.6%/yr |
| South Carolina | 12 | 678+1.8%/yr | +1.8%/yr | 1.1 | 0% | 1,120 in 2030+8.7%/yr |
| Oklahoma | 10 | 547−0.4%/yr | −0.4%/yr | 1.2 | 0% | 600 in 2030+1.5%/yr |
| Louisiana | 4 | 436−2.2%/yr | −2.2%/yr | 1.2 | 0% | 460 in 2030+1%/yr |
| Alabama | 5 | 408−7.8%/yr | −7.8%/yr | 1.0 | 0% | 380 in 2030−1.2%/yr |
| Arkansas | 7 | 373−2.3%/yr | −2.3%/yr | 1.1 | 0% | 450 in 2030+3.3%/yr |
| Kentucky | 5 | 339−1.5%/yr | −1.5%/yr | 0.8 | 0% | 370 in 2030+1.4%/yr |
| Mississippi | 9 | 334−6%/yr | −6%/yr | 1.0 | 0% | 280 in 2030−2.7%/yr |
| District of Columbia | 8 | 257+5.7%/yr | +5.7%/yr | 4.4 | 0% | 360 in 2030+5.7%/yr |
| West Virginia | 1 | 118+1.6%/yr | +1.6%/yr | 0.6 | 0% | 220 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 65 | 4,996−8%/yr | −8%/yr | 5.61.1× | 82% | 4,860 in 2030−0.5%/yr |
| Kidney stone management | 91 | 4,281+0.4%/yr | +0.4%/yr | 4.91.0× | 68% | 4,850 in 2030+2.1%/yr |
| Hysterectomy, hysteroscopy & ablation | 37 | 2,459−0.5%/yr | −0.5%/yr | 2.91.1× | 16% | 2,570 in 2030+0.7%/yr |
| Incontinence, prolapse & sacral neuromodulation | 35 | 1,664+1.9%/yr | +1.9%/yr | 1.90.7× | 34% | 1,940 in 2030+2.6%/yr |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in Maryland · Every state · Compare with Texas
Intuitive Surgical leads with 96% of company spending on these surgeons in 2025, −2 pts on 2024.
In 2025, 2 companies reported engagement with Maryland’s surgeons worth $116K in consulting, speaking, meals and travel tied to these products, about $7,747 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.